Semaglutide is approved by the Food and Drug Administration to treat Type 2 diabetes and chronic weight management, but not alcohol use disorder.

VA researchers are studying whether the GLP-1 receptor agonist may affect parts of the brain involved in reward, potentially offering a new treatment option for veterans with moderate or severe alcohol use disorder if proven safe and effective.

The department cautioned veterans not to self-medicate or replace evidence-based alcohol use disorder treatments with GLP-1 medications without first consulting a health care provider.

The study, known as the Cessation or Reduction of Alcohol Consumption in Veterans (CRAVE) trial, will enroll more than 600 veterans ages 18 to 80 at 18 VA medical centers nationwide.

Participants with moderate or severe alcohol use disorder will receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety evaluation. Researchers will measure changes in alcohol consumption, overall health and quality of life.

Researchers at Washington University School of Medicine have increasingly studied whether GLP-1 medications, originally developed for diabetes and later approved for obesity, could also help treat substance use disorders.

VA cited an analysis published in March that found patients taking GLP-1 medications experienced lower rates of alcohol use disorder and other substance use disorders than similar patients taking other diabetes medications.

The department said larger, controlled clinical trials are needed to determine whether semaglutide is safe and effective for treating alcohol use disorder.

In an official statement, VA Secretary Doug Collins said, “By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery.”

Recruitment began July 28. Veterans interested in participating can contact their local VA medical center or search for the trial on ClinicalTrials.gov.